



## Labcorp Introduces AI-Powered Real-World Data Platform with AWS and Datavant to Accelerate Alzheimer's Research

April 14, 2026

Platform leverages agentic AI and diverse healthcare datasets to transform and speed drug development

BURLINGTON, N.C., April 14, 2026 /PRNewswire/ -- [Labcorp](#) (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced a new AI-powered real-world data platform, designed to help researchers and biopharmaceutical companies analyze Alzheimer's disease-related data faster. Developed with [Amazon Web Services](#) (AWS) and [Datavant](#), the platform provides access to large, diverse datasets and advanced analytics—using deidentified, privacy-protected healthcare data—designed to accelerate scientific discovery, shorten drug development timelines and improve identification of patients for clinical trial recruitment. The platform enables researchers, biopharma companies, payors and contract research organizations to generate insights in minutes that previously required months of intensive data mining.



With more than [7.2 million](#) Americans living with Alzheimer's disease and annual care costs exceeding [\\$380 billion](#) in the U.S., accelerating drug development is critical. Traditionally, fragmented data and lengthy data preparation have slowed progress. Labcorp's platform addresses these challenges by leveraging standardized, direct-from-source laboratory data captured across millions of patients and advanced AI models to streamline data access and analysis. As a leader in neurology diagnostics, Labcorp offers the broadest blood-based biomarker testing portfolio for [Alzheimer's](#) disease and dementia, generating data that uniquely inform the depth, quality and scale of insights generated through this platform.

"This platform represents a powerful acceleration in Alzheimer's research," said Bola Oyegunwa, Ph.D., Labcorp's EVP and chief information and technology officer. "By combining AI, advanced analytics and the scale of Labcorp's diagnostic data, we're redefining what's possible—compressing months of manual data preparation into minutes. That shift enables researchers to focus on discovery instead of data engineering, accelerating the insights needed to drive better treatment decisions. Ultimately, this platform is about improving patient outcomes and delivering answers and hope faster for the millions of patients and families waiting for progress."

The platform represents a breakthrough in unifying healthcare research, combining Labcorp's extensive diagnostic and genomic datasets with medical claims, and, in future versions, electronic health record and social determinants of health data. Powered by advanced AI analytics, the platform can quickly identify patient cohorts, track disease progression patterns and measure treatment effectiveness across diverse populations.

Dr. Rowland Illing, chief medical officer and director, Healthcare and Life Sciences at AWS, emphasized the platform's transformative potential, "This collaboration between Labcorp and AWS shows how AI can help reduce the time from hypothesis to actionable insight from months to minutes, potentially shaving years off the drug development process. By leveraging AWS's AI services, including Amazon Bedrock to power the platform's agents and Amazon SageMaker for analyzing clinical trial and patient datasets, we're fundamentally changing the scope and scale of insights researchers can generate."

The platform's AI-powered analytics interface offers:

- Real-time, population-level analysis of treatment patterns, effectiveness and patient outcomes across diverse populations
- Characterization of patient segments tested for Alzheimer's disease
- Support for the selection of deidentified patient cohorts suitable for clinical trial recruitment based on defined inclusion and exclusion criteria

- Advanced statistical modeling tools to identify patient cohorts with unmet clinical need

The platform will complete its initial validation phase in spring 2026 and is expected to expand through 2026, incorporating additional data sources and analytical capabilities to further accelerate research insights including inflammatory diseases, cardiometabolic conditions, women's health and oncology.

This innovation extends Labcorp's broader real-world data strategy, leveraging AWS's AI-powered analytics and Datavant's privacy-preserving connectivity to enable secure, scalable analysis of de-identified healthcare data.

To learn more about Labcorp's AI-powered real-world data platform, visit <https://www.labcorp.com/biopharma/real-world-data-solutions/ai-platform/alzheimers>

#### **About Labcorp**

Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at [www.labcorp.com](http://www.labcorp.com).

#### **Cautionary Statement Regarding Forward-Looking Statements**

This press release contains forward-looking statements, including, but not limited to, statements with respect to the expected utility and benefits of Labcorp's real-world data platform for Alzheimer's disease research.

Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.

The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K under the heading RISK FACTORS and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS."

 View original content to download multimedia: <https://www.prnewswire.com/news-releases/labcorp-introduces-ai-powered-real-world-data-platform-with-aws-and-datavant-to-accelerate-alzheimers-research-302741607.html>

SOURCE Labcorp

Media: Alissa Lawver, [Media@labcorp.com](mailto:Media@labcorp.com); Investors: Dewey Steadman, [Investors@labcorp.com](mailto:Investors@labcorp.com)